Variable | N (%) |
---|---|
No. of patients | 357 |
Follow up time, months | |
Median | 36 |
Range | 0–179 |
Age, year | |
Median | 63 |
Range | 22–93 |
CA125 level | |
≤ 485 | 141 (53.2) |
> 485 | 124 (46.8) |
Ascites | |
No | 73 (29.1) |
Present | 178 (70.9) |
Optimal Debulking Surgery | |
Optimal | 245 (82.5) |
Suboptimal | 52 (17.5) |
Stage | |
I | 33 (9.8) |
II | 31 (9.2) |
III | 234 (69.2) |
IV | 40 (11.8) |
Primary Site of Disease | |
Ovarian | 300 (84.5) |
Primary Peritoneal | 53 (14.9) |
Fallopian Tube | 2 (0.6) |
Histologic subtype | |
Serous | 262 (73.6) |
Clear cell | 22 (6.2) |
Mucinous | 12 (3.4) |
Endometrioid | 25 (7.0) |
Other | 35 (9.8) |
Grade (FIGO) | |
1 | 7 (2.6) |
2 | 16 (6.1) |
3 | 240 (91.3) |
Recurrence | |
No | 64 (32.8) |
Yes | 131 (67.2) |
SNCG Immunoexpression | |
Negative | 100 (28) |
Positive | 257 (72) |
Status | |
Alive, No evidence of disease (ANED) | 67 (18.8) |
Alive, with evidence of disease (AWED) | 22 (6.2) |
Died of Disease (DOD) | 268 (75.0) |
Survival Time (months) | |
Median | 39 |
95 % CI | 34–44 |
Progression-free survival (months) | |
Median | 18 |
95 % CI | 15–23 |